VOLUNTARY ELECTRONIC REPORTING OF MEDICATION ERRORS AND ADVERSE DRUGS EVENTS DURING THE FIRST YEAR OF THE COVID-19 PANDEMIC

X. Larrea Urtaran1, A. Pérez Plasencia1, M. Coma Punset1, A. Dordà Benito1, C. Ortí Juan1, E. Nogué Pujadas1, G. López Noguera1, L. Gratacós Santanché1, C. Subirana Batlle1, R. Sacrest Güell1

1. University Hospital Dr. Josep Trueta, Pharmacy Department, Girona, Spain. 2. Institut d’Assistència Sanitària, Pharmacy Department, Salt, Spain.

Abstract number: SPSQ-104
26AC-0681
ATC code: S. Research performed on artificial model

BACKGROUND AND IMPORTANCE
Evidence regarding the rate of medication errors (ME) and adverse drugs events (ADE) during the pandemic of COVID-19 is few. In that period the rate of ME was potentially higher than average. Thus, voluntary hospital reporting systems are valuable sources of information on ME and ADE.

AIM AND OBJECTIVES
To describe the ME and ADE registered in the voluntary electronic notification system of our centre (TPSC Cloud®) during the first year of the COVID-19 pandemic and compare them with the same period of the previous year.

MATERIAL AND METHODS
Retrospective observational study of ME and ADE notified in the TPSC Cloud® from March 2020 to February 2021, compared with the period from March 2019 to February 2020.

RESULTS
249 incidents were reported from March 2020 to February 2021, which was 31.0% (n=361) less than in the previous period. The most common ME was prescription error in both periods (70.4% versus 67.3%).

The incident profile by typology was similar in both periods. The most frequent was ME that did not reach the patient, (40.2% versus 43.5%), followed by ME who reach the patient without ADE (23.4% versus 28.5%) (graphic 1).

Systemic anti-infectious drugs were the most involved in both periods (n=57; 22.9% versus n=73; 20.2%).

84 ADE without ME were reported from March 2020 to February 2021, representing an increase of 500% (n=14) compared with March 2019 to February 2020. 35 ADE of lopinavir/ritonavir and 4 of hydroxychloroquine used in the initial treatment of COVID-19 were notified.

The main notifier in both periods was the pharmacist (80.5% (graphic 2) versus 65.6%).

CONCLUSION AND RELEVANCE
During the first COVID-19 pandemic year, notifications of ME decreased, due to care load pressure, but incident profile was similar. Otherwise, ADE notifications increased notably, due to active pharmacovigilance carried out by pharmacists in off-label drugs used to treat the COVID-19.